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Abstract
Background: Increasing evidence suggests pharmacological treatments may impact on overall survival in Chronic
Obstructive Pulmonary Disease (COPD) patients. Individual clinical trials are rarely powered to detect mortality
differences between treatments and may not include all treatment options relevant to healthcare decision makers.
Methods: A systematic review was conducted to identify RCTs of COPD treatments reporting mortality; evidence
was synthesised using network meta-analysis (NMA). The analysis included 40 RCTs; a quantitative indirect comparison
between 14 treatments using data from 55,220 patients was conducted.
Results: The analysis reported two treatments reducing all-cause mortality; salmeterol/fluticasone propionate
combination (SFC) was associated with a reduction in mortality versus placebo in the fixed effects (HR 0.79;
95 % Crl 0.67, 0.94) but not the random effects model (0.79; 0.56, 1.09). Indacaterol was associated with a
reduction in mortality versus placebo in fixed (0.28; 0.08 to 0.85) and random effects (0.29; 0.08, 0.89) models.
Mean estimates and credible intervals for hazard ratios for indacaterol versus placebo are based on a small
number of events; estimates may change when the results of future studies are included. These results were
maintained across a variety of assumptions and provide evidence that SFC and indacaterol may lead to
improved survival in COPD patients.
Conclusion: Results of an NMA of COPD treatments suggest that SFC and indacaterol may reduce mortality.
Further research is warranted to strengthen this conclusion.
Keywords: COPD, COPD treatment, Systematic review, Meta-analysis, Mortality
Background
Chronic obstructive pulmonary disease (COPD) is an
important cause of morbidity across the world, and the
third leading cause of death globally [1, 2]. Primary pre-
vention by a combination of reducing tobacco exposure,
decreasing contact with biomass fuels and noxious gases
together with improved child health are the most effect-
ive ways of decreasing this burden in the longer term,
although it takes time for the benefits of interventions
on mortality to become apparent [3, 4]. In patients with
symptomatic COPD the impact of specific medications
on decreasing the risk of dying is an important consider-
ation and merits scientific consideration. The evidence
on mortality reduction from individual clinical trials in
COPD is inconclusive with relatively few studies of
duration and sample size sufficient to demonstrate an
impact [5].
Network meta-analysis (NMA) provides a statistical
approach to combining direct and indirect trial evidence
to generate relative treatment effects between different
drugs on outcomes of interest. In the absence of head-
to-head trials including all comparators, NMA has been
recommended by reimbursement agencies in the UK
and Germany [6, 7] and endorsed by influential bodies
such as ISPOR [8]. NMA has been applied to COPD
mortality data on two previous occasions [9, 10].
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We conducted a systematic review and network meta-
analysis (NMA) designed to assess whether pharmaco-
therapy affects mortality reported in COPD clinical
trials. NMA was then used to allow all treatment options
to be compared in a single analysis [11–13]. The analysis
combines survival data reported in two different forms:
total number of deaths (r) from (n) subjects subse-
quently referred to as the ‘binary endpoint’, and hazard
ratios which describe the impact of treatment on time to
death and account for censoring. Although hazard ratios
are more informative they are not reported in all studies
and the inclusion of binary data enables the maximum
number of trials to be included. Sensitivity analyses
permitted us to analyse the robustness of the results to
various assumptions supporting the base case analysis.
Primarily, our objective was to estimate the impact of
specific COPD treatments on patient mortality using
NMA. Secondly, we explored the strengths and limita-
tions of undertaking and interpreting NMA in this
context.
Methods
Systematic review
A systematic review was conducted to identify rando-
mised, blinded trials of COPD patients treated with
tiotropium, beclomethasone, budesonide, fluticasone
propionate, triamcinolone, bambuterol, formoterol, sal-
meterol, salbutamol, indacaterol, theophylline, roflumi-
last, indacaterol maleate, ipratropium bromide, vilanterol
trifenatate, fluticasone furoate or placebo. Dosing and
administration method were not specified in the inclu-
sion criteria. Combinations of the listed interventions
were allowed; dose comparison studies were not in-
cluded unless another listed intervention was also incor-
porated in the study. Studies were required to report all-
cause mortality in binary or hazard ratio form for at
least 24 weeks of follow-up; mortality could be reported
as a study outcome or as a serious adverse event. Only
English language full publications were included.
EMBASE (1988), MEDLINE, MEDLINE In-Progress
(1946) and CENTRAL (1898) were searched from
database inception to October 2012. Searches com-
bined controlled-vocabulary and free-text terms for
COPD and the treatments of interest; RCT filters were
used in EMBASE and MEDLINE. Full publications were
reviewed for inclusion by two analysts (JT and JC). Data
was extracted from eligible trials by one analyst with valid-
ation conducted by the second analyst. Dosages of the
same therapy were combined for the purposes of the
analysis (indacaterol (150 μg od, 300 μg od, 600 μg od),
budesonide (200 μg bid, 400 μg bid, 1200 μg od for 6
months followed by 800 μg od for 30 months), flutica-
sone propionate (250 μg bid, 500 μg bid), salmeterol
(50 μg bid, 100 μg bid), formoterol (6 μg bid, 12 μg bid,
24 μg bid) and salmeterol fluticasone propionate com-
bination (SFC) (50/ 250 μg bid, 50/ 500 μg bid)). The
Cochrane risk of bias tool was used to assess methods
of randomisation, allocation concealment, blinding, pa-
tient follow-up and incomplete reporting [14].
Statistical analysis
Binary mortality data: total number of deaths (r) from
(n) subjects, and hazard ratios with reported confidence
intervals from published studies meeting our inclusion
criteria were used as inputs to the analysis. We preferred
hazard ratios over binary data where reported. Hazard
ratios were taken from the Cox proportional-hazards
models as these were consistently reported, in particular
the Cox model for TORCH was preferred over that cal-
culated directly from the Kaplan Meier in accordance
with the other studies which reported HRs. Hazard ratio
data and binary data were combined using the method-
ology established in Woods [15] which also appropri-
ately incorporates multi-arm trials. Estimated treatment
effects were synthesised using network meta-analysis
(NMA) in a Bayesian multilevel framework. This method
allows simultaneous comparison of outcomes of multiple
treatments from trials comparing different sets of treat-
ment options (providing a connected network of treat-
ments can be formed) whilst retaining within-trial
randomisation. A study protocol was written and
reviewed prior to initiating the systematic review and
analysis. Full details of the statistical method and the
model code are provided in the Additional file 1.
The base case analysis included all RCTs meeting our
inclusion criteria using the intention to treat (ITT) re-
sults from these studies, combining different licensed
doses of the same medicines as single comparators.
Results are presented for active treatments relative to
placebo (reference).
Sensitivity analyses
The following pre-planned analyses were conducted to
examine the sensitivity of the study results to various
assumptions:
(A) Including on-treatment (OT) mortality (excluding
deaths that occurred to patients who ceased to
receive the allocated study treatment) results in
preference to ITT results where available.
(B) Meta-regression controlling for differences in
COPD severity assuming a common covariable
effect across treatments (assessed by baseline
FEV1 % predicted – mean value per study)
(C) Excluding studies where patients had high lung
function at baseline (mean FEV1 % predicted >65 %)
(D) Excluding studies where patients received
unlicensed doses
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(E) Excluding studies of less than 48 weeks duration
(F) Excluding studies not powered to detect a
difference in mortality
(G) Excluding studies that failed to meet our specified
quality assessment criteria (i.e. 2 or more
components of the assessment had a high or
unclear risk of bias) as assessed by the Cochrane
Collaboration risk of bias [14]
(H) Including studies from the Dong [10] NMA for
which mortality data were unavailable in the
primary publication. Dong [10] cited a variety of
sources for these data, including contacting the
study authors and searching website and clinical
trial registers; these were not included in the
present base case analysis
(I) Separating patients treated with tiotropium by type
of inhaler used (SoftMist or HandiHaler). Safety
concerns (increased mortality risk) had at the time
of the present analysis been raised around the
SoftMist inhaler [16]. We also incorporated the
results of TIOSPIR [17], a RCT of over 17,000
subjects designed to evaluate efficacy and safety
of the two different inhalers, in this sensitivity
analysis. TIOSPIR was not published until the
final writing up of the present study.
Statistical models were fitted using WinBUGS [18]. As
the present study is a Bayesian analysis we refer to cred-
ible intervals (the probability that the true value is
contained within the interval) rather than confidence
intervals; instead of statistically significant differences,
we refer to important differences (95 % credible interval
for hazard ratio does not cross 1.0).
Both fixed and random effect models were fitted. Fixed
effect assumes there is one true effect of each treatment
and that variation around this is attributed to chance
whilst random effects assume a distribution of effects
and that variance between studies is attributed to het-
erogeneity. Larger studies are thus attached relatively
less weight in random effects model [19]. The Deviance
Information Criteria (DIC) was calculated for each
model and used to assess whether any model should be
preferred [20]. Each model was run for a burn-in period
of 40,000 simulations, which were then discarded, with
parameter nodes monitored for a further 200,000 simu-
lations. Caterpillar and Brooks - Gelman - Rubin (BGR)
plots were used to compare results obtained using differ-
ent initial values, thus ensuring that the models had
converged [21].
Results and discussion
Systematic review
The systematic review identified 42 studies reporting all-
cause mortality in COPD patients (Fig. 1; reasons for
excluding full publications: Additional file 2: Table S1).
Demographic characteristics of subjects (age, gender) are
reported in Table 1; the impact of differences in baseline
FEV1 % predicted is assessed in sensitivity analyses B
and C. The proportion of current smokers was similar
across trials, but three trials (all with patients with less
impairment of lung function) reported levels in excess of
75 % [22–24].
Assessment of study quality using the Cochrane risk of
bias tool found that the quality of study reporting was
generally high (Additional file 2: Table S2). Although all
trials were randomised, 17 did not adequately describe
the method of randomisation; [22, 24–39] and two stud-
ies did not adequately describe methods for allocation
concealment [37, 39]. With the exception of FICOPD II
where the theophylline arm (not included in analysis)
was open-label [36], all studies were double-blind.
Reporting of loss to follow-up was unclear in 17 studies;
[22, 23, 27, 29, 30, 32, 34, 37, 40–47] imbalanced drop-
outs between the treatment groups in two studies was
considered to result in a high risk of bias for the re-
ported outcome data [39, 48]. In nine studies two or
more components of the assessment were found to be
potentially associated with an unclear or high risk of bias
[22, 24, 27, 29, 30, 32, 34, 37, 39]. This was thought to
reflect incomplete reporting rather than underlying
methodological weakness in many cases.
Studies included in the analysis
Two studies were excluded from the statistical ana-
lysis. Campbell [49], was excluded since the treatment
arms in this trial (formoterol + formoterol as needed,
formoterol + terbutaline as needed, placebo + terbutaline
as needed) were not included in any of the other tri-
als analysed, and therefore did not link to the evi-
dence network. Similarly, Kerstjens [41], comparing
terbutaline with ipratropium bromide + terbutaline and
beclomethasone + terbutaline, did not connect to the main
evidence network. Two treatments were excluded from
the statistical analysis. Theophylline was included in a sin-
gle trial, FICOPD II (Rossi [36]), which reported no
deaths, and so it was not possible for a hazard ratio to be
estimated for this treatment. Similarly, the only trial in-
cluding tiotropium + formoterol combination (Vogelmeier
[38]) did not report any deaths for this arm, which was
therefore also excluded from the analysis. The other treat-
ment arms of these studies were included in the analysis.
The statistical analysis was based on 40 RCTs includ-
ing 55,220 randomised subjects and 88,261 person years
of experience, allowing the comparison of 14 treatments.
Figure 2 shows the base case evidence network weighted
by the number of person-years of follow up for each
within-trial comparison. Reported binary mortality out-
comes are presented in Table 1 and hazard ratios in
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Table 2. In the base case analysis hazard ratios for all-
cause mortality were available for three studies and bin-
ary data were available for the remaining 37 studies.
Base case results
Results from the fixed and random effects base case ana-
lysis are presented in Fig. 3. Hazard ratios for each treat-
ment are compared to placebo; a hazard ratio below 1.0
indicates that the treatment is associated with reduced
mortality compared to placebo. There was no evidence
to suggest that the random effects model was a better fit
than the fixed effects model; a difference in DIC of 2–3
is required to be indicative of improved model fit [20].
However, if we believe there is true heterogeneity be-
tween the trials, the random effects model would be
more appropriate.
Two interventions produced a hazard ratio relative to
placebo that did not cross 1.0 using the fixed effects
model. SFC was associated with a reduction in mortality
of 21 % (HR 0.79; 95 % CrI 0.67, 0.94) and indacaterol
with a mortality reduction of 72 % (HR 0.28; 95 % Crl
0.08, 0.85). Using a random effects model SFC failed to
show evidence of effect (HR 0.79; 95 % CrI 0.56, 1.09).
For indacaterol the result using the random effects
model (HR 0.29; 95 % CrI 0.08, 0.89) was comparable to
that using the fixed effects model. No evidence of effect
on all-cause mortality (versus placebo) was found for
other treatments. Although the results for most com-
parators have wide credible intervals suggesting incon-
clusive results, the HRs for tiotropium+ salmeterol,
tiotropium + SFC and beclomethasone + formoterol have
particularly wide credible intervals; in each case the results
are generated by single, relatively small study arms there-
fore the uncertainty around the estimates is high.
Sensitivity analyses
Results of the sensitivity analyses did not in general
differ markedly from the base case (Additional file 2:
Table S3). For SFC vs placebo the relative treatment
effect improved in the fixed effects analysis when
unlicensed doses were excluded, but results from the
random effects model showed no evidence of effect and
were similar to the base case. Similarly, the relative treat-
ment effect for indacaterol vs placebo strengthened
slightly (HR 0.17, 95 % CrI 0.03, 0.78) when studies with
a shorter duration were excluded.
Conclusion
In this NMA, data from 40 trials were used to inform
comparisons of mortality associated with 14 different
pharmacological treatments for COPD. The method al-
lows comparisons of treatments not compared directly
n= 5,513 records identified through 
database searching:
MEDLINE & MEDLINE in-process 
(n=2,092)
EMBASE (n=1,449)
CENTRAL (n=2,272)
n=3,446 records after duplicates 
removed
n=159 full-text articles assessed for 
eligibility
n=40 studies included in NMA
n= 3,446 records screened for eligibility n=3,287 Records excluded 
n=117 full-text articles 
excluded, with reasons:
n=62 < 6 month duration
n=27 mortality not reported
n=9 letter/review/comment
n=3 two trials combined
n=2 non-
randomised/blinded
n=14 other
n=42 full-text article included in 
systematic review
n=2 Records disconnected 
from the main network, 
therefore excluded from 
analysis
Fig. 1 PRISMA diagram showing inclusion of studies at each stage of the systematic review and network meta-analysis
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Table 1 Baseline characteristics of included studies and all-cause mortality (binary data)
Baseline characteristics All-cause mortality (binary)
References Trial Treatment Dose Study duration
(weeks)
n Mean
age (yr.)
Women
(%)
Current
smokers (%)
FEV1 (mean %
predicted)
Subjects Deaths - ITT Deaths – OT
[53] Aaron 2007 Tiotropium + Salmeterol 18 μg od/50 μg bid 52 148 67.6 42.6 24.3 41.2 148 6 NR
Tiotropium + SFC 18 μg od/50/500 μg bid 145 67.5 42.1 32.4 42.2 145 6 NR
Tiotropium + Placebo 18 μg od 156 68.1 46.2 26.9 42.1 156 4 NR
[40] Anzueto 2009 SFC 50/250 μg bid 52 394 65.4 49.0 42.0 41.2 394 4 NR
Salmeterol 50 μg bid 403 65.3 43.0 43.0 40.0 403 6 NR
[54] Bateman 2010 Tiotropium 5 μg od 48 1952 64.8 21.9 35.7 45.2 1952 52 NR
Placebo - 1965 64.8 23.0 35.9 45.4 1965 38 NR
[55] ISOLDE
(Burge 2000)
Fluticasone Propionate 500 μg bid 156 376 63.7 25.0 36.4 50.3 372 32 NR
Placebo - 375 63.8 26.0 39.2 50.0 370 36 NR
[56] Calverley 2003 Budesonide + Formoterol 320/9 μg bid 52 254 64.0 22.0 33.0 36.0 254 5 NR
Budesonide 400 μg bid 257 64.0 26.0 39.0 36.0 257 6 NR
Formoterol 9 μg bid 255 63.0 25.0 36.0 36.0 255 13 NR
Placebo - 256 65.0 25.0 30.0 36.0 256 5 NR
[5] TORCH*
(Calverley 2007)
Fluticasone Propionate 500 μg bid 156 1534 65.0 25.0 43.0 44.1 1534 246 NR
Salmeterol 50 μg bid 1521 65.1 24.0 43.0 43.6 1521 205 NR
SFC 50/500 μg bid 1533 65.0 25.0 43.0 44.3 1533 193 NR
Placebo - 1524 65.0 24.0 43.0 44.1 1524 231 NR
[57] Calverley 2007 Roflumilast 500 μg od 52 760 65.0 25.0 38.0 41.0 760 12 NR
Placebo 753 64.0 24.0 35.0 41.0 753 20 NR
[58] M2-124
(Calverley 2009)
Roflumilast 500 μg od 52 765 64.0 29.0 48.0 37.6 765 17 NR
Placebo 758 63.0 29.0 48.0 37.5 758 17 NR
M2-125
(Calverley 2009)
Roflumilast 500 μg od 52 772 64.0 21.0 35.0 34.6 772 25 NR
Placebo 796 64.0 19.0 35.0 35.3 796 25 NR
[59] Calverley 2010 Beclomethasone +
Formoterol
200/12μg bid 48 232 63.0 20.7 38.8 41.9a 232 2 NR
Budesonide + Formoterol 400/12μg bid 238 64.1 18.5 36.1 42.3a 238 4 NR
Formoterol 12 μg bid 233 63.7 18.9 37.3 42.5a 233 0 NR
[49] Campbell 2005 Formoterol bid + Formoterol 9 μg bid / 4.5 μg as
needed
26 225 60.0 29.0 56.0 54.4b 225 1 NR
Formoterol bid + Terbutaline 9μg bid / 0.5 mg as
needed
215 60.0 39.0 54.0 53.0b 215 2 NR
Placebo + Terbutaline 0.5 mg as needed 217 60.0 27.0 55.0 54.1b 217 0 NR
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Table 1 Baseline characteristics of included studies and all-cause mortality (binary data) (Continued)
[26] Casaburi 2005 Tiotropium 18 μg od 25 55 65.9 45.5 29.1 32.6b 55 1 NR
Placebo - 53 67.3 41.5 18.9 36.2b 53 0 NR
[27] Chan 2007 Tiotropium 18 μg od 48 608 66.8 41.0 32.0 39.4b 608 15 13
Placebo - 305 66.9 39.0 30.0 39.3b 305 4 2
[60] Choudhury 2007 Fluticasone Propionate 500 μg bid 52 128 67.6 52.0 40.6 53.2 128 3 NR
Placebo - 132 67.3 44.0 35.6 55.0 132 0 NR
[28] INVOLVE
(Dahl 2010)
Indacaterol (300) 300μg od 52 437 64.0 19.7 NR 51.5 437 1 1
Indacaterol (600) 600μg od 425 63.0 23.1 NR 50.8 428 1 0
Formoterol 12μg (bid) 434 64.0 19.8 NR 52.5 435 5 3
Placebo - 432 63.0 18.5 NR 52.0 432 5 4
[29] Donohue 2002 Salmeterol 50 μg bid 26 213 64.6 25.0 NR 40.2bc 213 3 NR
Tiotropium 18 μg od 209 64.5 26.0 NR 40.2bc 209 0 NR
Placebo - 201 65.6 25.0 NR 40.2bc 201 4 NR
[30] INHANCE
(Donohue 2010)
Indacaterol (150) 150 μg od 26 416 63.4 37.7 NR 56.1 416 1 NR
Indacaterol (300) 300 μg od 416 63.3 36.8 NR 56.3 416 0 NR
Tiotropium 18 μg od 415 64.0 35.2 NR 53.9 415 2 NR
Placebo - 418 63.6 39.0 NR 56.1 418 0 NR
[31] Ferguson 2008 SFC 250/50 μg bid 52 394 64.9 42.0 40.0 39.8 394 6 NR
Salmeterol 50 μg bid 388 65.0 48.0 38.0 40.6 388 3 NR
[32] Hanania 2003 Fluticasone Propionate 250 μg bid 24 183 63.0 34.0 48.0 42.0b 183 0 NR
Salmeterol 50 μg bid 177 64.0 42.0 51.0 42.0 177 0 NR
SFC 250 / 50 μg bid 178 63.0 39.0 43.0 41.0 178 0 NR
Placebo - 185 65.0 32.0 47.0 42.0b 185 0 NR
[33] VIVACE
(Kardos 2007)
Salmeterol 50 μg bid 44 487 64.0 22.4 44.4 40.3 487 9 NR
SFC 50/500 μg bid 507 63.8 26.0 40.6 40.4 507 7 NR
[41] Kerstjens 1992 Ipratropium Bromide +
Terbutaline
800/2000 μg bid 130 92 38.9 36.0 34.0 63.3a 92 0 NR
Beclomethasone +
Terbutaline
160/2000 μg bid 91 40.2 35.0 36.0 64.6a 91 0 NR
Placebo + Terbutaline na/2000 μg bid 91 39.6 36.0 37.0 63.3a 91 0 NR
[42] INLIGHT-2
(Kornmann 2011)
Indacaterol 150 μg od 26 330 63.0 28.0 46.0 54.0 330 1 NR
Salmeterol 50 μg bid 333 63.0 25.0 46.0 53.0 333 0 NR
Placebo - 335 64.0 23.0 45.0 53.0 335 3 NR
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Table 1 Baseline characteristics of included studies and all-cause mortality (binary data) (Continued)
[34] Mahler 2002 Fluticasone Propionate 500 μg bid 24 168 64.4 39.0 46.0 41.0b 168 0 NR
Salmeterol 50 μg bid 160 63.5 36.0 46.0 40.0b 160 0 NR
SFC 50 / 500 μg bid 165 61.9 38.0 46.0 41.0b 165 0 NR
Placebo - 181 64.0 25.0 54.0 41.0b 181 3 NR
[61] Niewoehner 2005 Tiotropium - 26 914 67.6 2.0 29.0 35.6b 914 22 NR
Placebo 18 μg od 915 68.1 1.0 30.0 35.6b 915 19 NR
[22] EUROSCOP
(Pauwels 1999)
Budesonide 400μg bid 156 634 52.5 26.5 100.0 76.8a 634 8 NR
Placebo - 643 52.4 27.8 100.0 76.9a 643 10 NR
[35] Rennard 2009 Budesonide + Formoterol 320/9 μg bid 52 494 63.2 37.7 39.1 38.6 494 8 3
Budesonide + Formoterol 160/9 μg bid 494 63.6 37.2 41.9 39.6 494 8 6
Formoterol 9 μg bid 495 62.9 34.7 45.1 39.3 495 6 2
Placebo - 481 62.9 34.7 43.9 40.8 481 8 4
[36] FICOPD II
(Rossi 2002)
Formoterol 12 12 μg bid 52 211 63.0 13.0 NR 47.0b 211 3 NR
Formoterol 24 24 μg bid 214 62.0 17.0 NR 47.0b 214 1 NR
Theophylline 200/300 mg bid 209 64.0 18.0 NR 46.0b 209 0 NR
Placebo - 220 63.0 21.0 NR 49.0b 220 0 NR
[62] Schermer 2009 Fluticasone Propionate 500 μg bid 156 94 58.4 27.0 62.0 68.7b 94 8 NR
Placebo - 96 59.6 32.0 51.0 71.4b 96 3 NR
[23] Shaker 2009 Budesonide 400 μg bid 208 127 63.6 38.0 100.0 51.0b 127 5 NR
Placebo - 127 63.6 46.0 100.0 53.0b 127 5 NR
[43] Stockley 2006 Salmeterol 50 μg bid 52 318 62.3 24.0 46.0 45.8b 216 6 NR
Placebo - 316 62.4 23.0 47.0 46.1b 222 5 NR
[37] Szafranski 2003 Budesonide + Formoterol 320/9 μg bid 52 208 64.0 24.0 30.0 36.0b 208 6 NR
Budesonide 400 μg bid 198 64.0 20.0 36.0 37.0b 198 5 NR
Formoterol 9 μg bid 201 63.0 24.0 38.0 36.0b 201 6 NR
Placebo - 205 65.0 17.0 34.0 36.0b 205 9 NR
[63] Tashkin 2008 Budesonide + Formoterol 320/9 μg bid 26 277 63.1 32.1 44.4 39.1 277 3 NR
Budesonide + Formoterol 160/9 μg bid 281 63.6 35.6 44.8 39.9 281 4 NR
Budesonide + Formoterol 320 + 9 μg bid (separate) 287 63.7 25.8 41.5 39.2 287 0 NR
Budesonide 320 μg bid 275 63.4 32.4 42.9 39.7 275 2 NR
Formoterol 9 μg bid 284 63.5 34.5 41.9 39.6 284 1 NR
Placebo - 300 63.2 31.0 39.7 41.3 300 1 NR
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Table 1 Baseline characteristics of included studies and all-cause mortality (binary data) (Continued)
[64, 65] UPLIFT (Tashkin
2008/Celli 2009)
Tiotropium 18 μg od 208 2986 64.5 24.6 29.3 47.7 2987 446 381
Placebo - 3006 64.5 26.1 29.9 47.4 3006 495 411
[44] Tonnel 2008 Tiotropium 18 μg od 39 266 64.9 13.2 23.7 47.5b 266 3 NR
Placebo 288 63.5 14.6 30.2 46.2b 288 6 NR
[45] COPE
(van der Valk 2002)
Fluticasone Propionate 500 μg bid 26 123 64.1 14.6 22.0 57.5 123 1 NR
Placebo - 121 64.0 16.5 33.3 56.1 121 1 NR
[46] CCLS (Vestbo 1999) Budesonide 800 μg od + 400 μg od
for 6 months; 400 μg
bid for 30 month
156 145 59.0 41.4 75.9 86.2 145 4 NR
Placebo - 145 59.1 37.9 77.2 86.9 145 5 NR
[38] Vogelmeier 2008 Formoterol 10 μg bid 24 210 61.8 24.3 NR 51.6b 210 0 NR
Tiotropium 18 μg od 221 63.4 20.8 NR 51.6b 221 0 NR
Tiotropium + Formoterol 18 μg od/10 μg bid 207 62.6 20.8 NR 50.4 207 0 NR
Placebo - 209 62.5 22.5 NR 51.1 209 1 NR
[47] POET-COPD 2011
(Vogelmeier 2011)
Tiotropium 18 μg od 52 3707 62.9 25.6 48.0 49.2 3707 64 66
Salmeterol 50 μg bid 3669 62.8 25.1 48.3 49.4 3669 78 73
[66] INSPIRE
(Wedzicha 2008)
SFC 50/500 μg bid 104 658 64.0 19.0 38.0 39.1 658 21 18
Tiotropium 18 μg od 665 65.0 16.0 38.0 39.4 665 38 34
[24] LHS (Wise 2000) Triamcinolone 600 μg bid 156 559 56.2 36.0 90.5 68.5 559 15 NR
Placebo - 557 56.4 37.9 89.8 67.2 557 19 NR
[39] Zheng 2007 SFC 50/500 μg bid 24 297 66.0 9.4 21.0 47.0b 297 2 NR
Placebo - 148 66.6 13.5 23.0 47.0b 148 0 NR
[48] Zhong 2012 Budesonide + Formoterol 320/9 μg bid 26 156 65.7 1.9 NR 36.2 156 1 NR
Budesonide 400 μg bid 152 64.7 7.9 NR 36.3 152 0 NR
FEV1 – mean % predicted, post-bronchodilator
*Powered to detect mortality
aMean % predicted FEV1 is pre-bronchodilator
bNot stated whether mean % predicted FEV1 is pre-bronchodilator or post-bronchodilator
cFEV1 is mean of the three treatment arms
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within individual RCTs, and provides additional informa-
tion on the relative efficacy of treatments for which dir-
ect trial comparisons are available. The results show that
only indacaterol and the combination of the long-acting
β2-agonist salmeterol and the inhaled corticosteroid
fluticasone propionate (SFC) are associated with an im-
portant reduction in the risk of all-cause mortality in
COPD in fixed effect models. Although the fixed effects
model was presented as the base case there was no clear
difference between the fixed and random effects models
Fig. 2 Base case evidence network. The width of the lines are proportional to the total person years of follow-up for all trials informing
that comparison
Table 2 All-cause mortality (hazard ratios) of included studies
Trial Treatment Comparator ITT On treatment
HR LCI UCI p value HR LCI UCI p value
TORCH SFC Placebo 0.811 0.670 0.982 0.030 NR NR NR NR
SFC Salmeterol 0.946 0.777 1.151 0.580 NR NR NR NR
SFC Fluticasone propionate 0.768 0.636 0.927 0.006 NR NR NR NR
Salmeterol Placebo 0.857 0.710 1.035 0.110 NR NR NR NR
Fluticasone propionate Placebo 1.056 0.883 1.264 0.550 NR NR NR NR
UPLIFT Tiotropium Placebo 0.890 0.790 1.020 0.086 0.840 0.730 0.970 0.016
POET-COPD Tiotropium Salmeterol 0.810 0.580 1.130 0.210 0.850 0.610 1.190 0.350
INSPIRE SFC Tiotropium NR NR NR NR 0.480 0.270 0.850 0.012
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(both of which are presented). The results were consist-
ent across a number of sensitivity analyses including
controlling for disease severity.
Results for SFC are based on 233 deaths occurring in
7427 subject years. The results for indacaterol are based
on four deaths occurring over 1446 subject years and
have wide credible intervals. These results are sensitive
to the number of deaths (a small change will have a large
impact on the resulting HR) and may change with fur-
ther research.
The results for many of the treatments are inconclu-
sive, as demonstrated by the wide credible intervals ex-
hibited around a number of the HRs. Whilst tighter
credible intervals are observed around the results for tio-
tropium, salmeterol and fluticasone, our analysis is still
inconclusive as to whether the treatments provide a
greater benefit or harm to patients.
Two published NMAs have evaluated the relationship
between pharmacological agents and mortality in COPD
patients [9, 10]. Dong [10] considered all-cause mortality
and cardiovascular death as outcomes: 42 trials pub-
lished up to July 2011 were included, treatments were
grouped by class (long-acting β2 agonists, inhaled corti-
costeroids etc.) and tiotropium was separated by inhaler
type. The authors sourced trial mortality results from
secondary sources. The study reported a reduction in
mortality for LABAs combined with ICS compared with
placebo (HR 0.80; 95 % CrI 0.67, 0.94) based on a fixed
effects model. Baker [9] included 28 trials reporting the
mortality published up to October 2007: treatments
Fig. 3 Forest plot of results of network meta-analysis. Hazard ratios compared to placebo (DIC 431.9 FE, 431.5 RE). SFC = Salmeterol fluticasone
propionate combination; CrI = credible interval; Doses were pooled for the purpose of the analysis: indacaterol (150 μg od, 300 μg od), budesonide
(200 μg bid, 400 μg bid, 1200 μg od for 6 months followed by 800 μg od for 30 months), fluticasone propionate (250 μg bid, 500 μg bid), salmeterol
(50 μg bid, 100 μg bid), formoterol (6 μg bid, 12 μg bid, 24 μg bid) and salmeterol fluticasone propionate combination (SFC) (50/250 μg bid,
50/500 μg bid)
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were grouped by class. A mortality reduction reported
for LABAs in combination with ICS vs placebo (HR
0.71; 95 % CrI 0.49, 0.96) in the fixed effect model.
The present analysis included an additional 14 months
of reported evidence and a wider range of treatments
(roflumilast, indacaterol and triamcinolone) compared
with Dong [10]. Furthermore, results were not aggre-
gated by class. An assumption of class effects presup-
poses that the effect of each intervention within a class
is identical. Even if the assumption holds for efficacy
data it may not translate to safety data as interventions
could have physiological effect other than the mechan-
ism of action, therefore we chose estimate effects for
each intervention independently [50].
Binary and hazard ratio data were combined in the
same analysis, permitting the maximum number of stud-
ies to be included and using the best available data from
each. We minimised the risk of errors by using data only
from citable sources. Sensitivity analyses were under-
taken to examine the robustness of the results to the
underlying assumptions.
There are a number of limitations of this study. NMA
methods depend on the assumptions that effect mea-
sures are additive on the selected scale and that relative
treatment effects are comparable; [8] heterogeneity be-
tween trials may invalidate this assumption. Potential
observed or unobserved differences between trials may
impact on heterogeneity and thereby relative treatment
effects.
The majority of the studies included were not specific-
ally designed to capture mortality as a primary or sec-
ondary endpoint. The feasibility of conducting RCTs
powered to detect differences in mortality in COPD pa-
tients is limited by the need for large sample sizes with
sufficient follow-up, as well as the potential for introdu-
cing bias associated with differential dropout rates across
study arms. Although this is a limitation of the current
analysis, where there is an absence of head-to-head
trials including all comparators, NMA is a useful tool
for healthcare decision makers. In the present analysis
we only included studies which reported mortality in
the primary study publication. Inclusion of other
studies where mortality is available in secondary pub-
lications may influence the results however the rela-
tively small number of deaths in these trials makes
this unlikely [10].
A potentially beneficial impact on mortality could be
masked if a large number of studies with low or ineffec-
tual dosages are included. Whilst there is some evidence
that dose responsiveness may not be a significant factor
in COPD [17, 51], this could be explored further by ex-
tending the network to incorporate dose finding studies
and by implementing a three-level hierarchical NMA
model with an additional level for each drug class [52].
Whilst we controlled for disease severity (recorded by
baseline lung function) we did not control for other po-
tential differences between trials which may impact on
relative treatment effects (e.g. background therapy, his-
tory of exacerbations) as reporting was less consistent
for these indicators.
Further work could examine baseline risk or the re-
sponse in the placebo arms between studies. For ex-
ample, similar rates of death per 1000 patient years (PY)
were observed in the indacaterol (9.9/1000 PY), budeso-
nide (10.0/1000 PY) and triamcinolone (11.4/1000 PY)
placebo arms. Much higher rates were observed in the
tiotropium (37.2/1000 PY), fluticasone propionate (43.3/
1000 PY), salmeterol (47.0/1000 PY) and SFC (48.7/1000
PY) placebo arms (strongly influenced by the size and
number of deaths in TORCH and UPLIFT) (Additional
file 2: Table S4).
We conclude that currently available data from clinical
trials in COPD suggest that some pharmacological treat-
ments may have a significant impact on mortality, com-
pared with placebo. In particular indacaterol and the
combination of salmeterol and fluticasone propionate
have shown evidence of reduction in all-cause mortality.
The result for indacaterol is however based on a small
number of deaths occuring to subjects receiving this
therapy. Further research is warranted to strengthen our
conclusions.
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